Skip to content

Liposomal Bupivacaine in Rhomboid intercostal and subserratus plane block: A Randomized Controlled Study of Safety and Efficacy

Effect of liposomal bupivacaine for Rhomboid intercostal and subserratus plane block on postoperative analgesia after video-assisted thoracoscopic surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107186
Enrollment
Unknown
Registered
2025-08-06
Start date
2025-08-07
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

liposomal bupivacaine group:20ml 266mg liposomal bupivacaine +20ml 0.9% physiological saline
ropivacaine group:10ml 100mg ropivacaine + 30ml 0.9% physiological saline

Sponsors

The Second Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients who plan to undergo thoracoscopic partial lung resection surgery (lung wedge, lung segment, lobe) under general anesthesia, the estimated operation time is >=1 hour; 2. Age>=18 years old; 3. BMI index 18-30kg/?; 4. ASA grade I to II; 5. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Refusal to participate in this study; 2. Communication disorders, inability to cooperate with researchers, such as language comprehension disorders, mental illness, epilepsy, Parkinson's history or myasthenia gravis, etc.; 3. Those who are allergic to the drugs in this study 4. History of chronic pain such as neuropathic pain before surgery 5. Those who have a history of alcohol, analgesic drugs or other drug abuse and addiction; 6. Those who have participated in other clinical trials within 3 months before being selected for the study; 7. The doctor in charge or the investigator believes that there are other situations that are not suitable for participating in this study (the reason needs to be recorded);

Design outcomes

Primary

MeasureTime frame
The incidence of pain two days after postoperation;

Secondary

MeasureTime frame
QoR-40(Quality of Recovery-40);postoperative nausea and vomiting incidence;Recovery time (min);postoperative dizziness incidence;the satisfaction scores;postoperative analgesic dosage (mg);patient-controlled analgesia (PCA) demand count;Sufentanil(ug);Propofol (mg);postoperative pulmonary complications incidence;

Countries

China

Contacts

Public ContactChangjun Gao

The Second Affiliated Hospital of Air Force Military Medical University

gaocj74@163.com+86 29 8477 7439

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026